1. EGFR-Targeted Therapies: A Literature Review
   Calista Sha et al, 2024, Journal of Clinical Medicine CrossRef
2. Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC
   Emiliano Laudadio et al, 2024, ACS Chemical Biology CrossRef
3. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
   Byoung C. Cho et al, 2024, New England Journal of Medicine CrossRef
4. Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs)
   Lulin Zhu et al, 2024, Drug Metabolism Reviews CrossRef
5. Identification of expression profiles and transcription factors during EGFR‐TKI acquired resistance in LUAD
   Lili Feng et al, 2024, Precision Medical Sciences CrossRef
6. Dark under the Lamp: Neglected Biological Pollutants in the Environment Are Closely Linked to Lung Cancer
   Dongjie Wang et al, 2024, International Journal of Molecular Sciences CrossRef
7. Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer
   Zaheer Qureshi et al, 2024, American Journal of Clinical Oncology CrossRef
8. The Agonistic Activity of the Human Epidermal Growth Factor is Reduced by the D46G Substitution
   Anastasia Aleksandrovna Akunevich et al, 2024, Protein & Peptide Letters CrossRef
9. Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
   Mohammed Hawash, 2024, Cells CrossRef
10. Successful rapid improvement of acute respiratory distress syndrome induced by EGFR-mutated non-small cell lung cancer with almonertinib: a case report
    Cheng Sun et al, 2024, BMC Pulmonary Medicine CrossRef
11. Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy
    Ya-Tao Wang et al, 2024, Molecules CrossRef